Exact Sciences to Highlight Cologuard^® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025

Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test

Exact Sciences Launches the Cologuard™ Plus Test, Transforming Colorectal Cancer Screening

Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy

Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement

New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion

Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy

Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW^® 2024

Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to inform treatment

Exact Sciences Announces Preliminary Fourth Quarter 2023 Results